Page last updated: 2024-11-10

tak-220

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TAK-220: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5275766
CHEMBL ID207004
SCHEMBL ID3034679
MeSH IDM0493910

Synonyms (31)

Synonym
1-acetyl-n-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-n-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
gtpl800
tak 220
tbr-220
tbr220
tak220
4-piperidinecarboxamide, 1-acetyl-n-[3-[4-[[4-(aminocarbonyl)phenyl]methyl]-1-piperidinyl]propyl]-n-(3-chloro-4-methylphenyl)-
tak-220
1-acetyl-n-[3-[4-[(4-carbamoylphenyl)methyl]-1-piperidyl]propyl]-n-(3-chloro-4-methyl-phenyl)piperidine-4-carboxamide
1-acetyl-n-{3-[4-(4-carbamoylbenzyl)piperidin-1-yl]propyl}-n-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
bdbm50185979
L000798
CHEMBL207004 ,
928qin0r16 ,
333994-00-6
unii-928qin0r16
1-acetyl-n-(3-{4-((4-carbamoylphenyl)methyl)piperidin-1-yl}propyl)-n-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
4-piperidinecarboxamide, 1-acetyl-n-(3-(4-((4-(aminocarbonyl)phenyl)methyl)-1-piperidinyl)propyl)-n-(3-chloro-4-methylphenyl)-
SCHEMBL3034679
AC-31370
CS-5579
HY-19974
DTXSID00187027
AKOS027337128
1-acetyl-n-(3-(4-(4-carbamoylbenzyl)piperidin-1-yl)propyl)-n-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
Q27088928
SB16979
P14972
A913339
MS-30105
NCGC00522444-01

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Since TAK-652 is orally bioavailable and has favorable pharmacokinetic profiles in humans, it is considered a promising candidate for an entry inhibitor of HIV-1."( Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.
Baba, M; Miyake, H; Okamoto, M; Takashima, K; Wang, X, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-C chemokine receptor type 5Homo sapiens (human)IC50 (µMol)0.00200.00020.25679.0000AID264206; AID264207
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (20)

Processvia Protein(s)Taxonomy
MAPK cascadeC-C chemokine receptor type 5Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 5Homo sapiens (human)
chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 5Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 5Homo sapiens (human)
release of sequestered calcium ion into cytosol by sarcoplasmic reticulumC-C chemokine receptor type 5Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 5Homo sapiens (human)
signalingC-C chemokine receptor type 5Homo sapiens (human)
symbiont entry into host cellC-C chemokine receptor type 5Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
response to cholesterolC-C chemokine receptor type 5Homo sapiens (human)
cellular response to lipopolysaccharideC-C chemokine receptor type 5Homo sapiens (human)
negative regulation of macrophage apoptotic processC-C chemokine receptor type 5Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 5Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 5Homo sapiens (human)
immune responseC-C chemokine receptor type 5Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
virus receptor activityC-C chemokine receptor type 5Homo sapiens (human)
actin bindingC-C chemokine receptor type 5Homo sapiens (human)
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 5Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
protein bindingC-C chemokine receptor type 5Homo sapiens (human)
coreceptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 5Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 5Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
endosomeC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cytoplasmC-C chemokine receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID264215Antiviral activity against R5 HIV1 JR-FL replication in human PBMC2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID264213Inhibition of CCR4 expressed in CHO cells at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID264207Inhibition of membrane fusion between HIV1 JR-FL Env-expressing COS7 cells and MOLT4/CCR52006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID264217Cytotoxicity against human PBMC at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID1256138Antinociceptive activity in normal ICR-CD1 mouse assessed as withdrawal latency for radiant heat at 1000 pmol, it by tail flick assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).
AID237848Oral bioavailability in fasted rats2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
New approaches toward anti-HIV chemotherapy.
AID264208Stability in human liver microsome after 20 mins2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID1256153Selectivity ratio of ED50 for antinociceptive activity in i.c.v dosed LPS-induced ICR-CD1 mouse thermal hyperalgesia model to ED50 for i.t dosed LPS-induced ICR-CD1 mouse thermal hyperalgesia model2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).
AID1256139Antinociceptive activity in normal ICR-CD1 mouse assessed as withdrawal latency for radiant heat at 1000 pmol, icv by tail flick assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).
AID264218Plasma concentration in cynomolgus monkey at 5 mg/kg, po after 0.7 hrs2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID1256147Antinociceptive activity in LPS-induced ICR-CD1 mouse thermal hyperalgesia model assessed as withdrawal latency for radiant heat at 1000 pmol i.t by tail flick assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).
AID264221Oral bioavailability in cynomolgus monkey at 5 mg/kg, po2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID264219Plasma half life in cynomolgus monkey at 5 mg/kg, po2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID264220AUC(0-24h) in cynomolgus monkey at 5 mg/kg, po2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID279328Antiviral activity in long term culture of HIV1 KK infected PBMCs after 67 passages assessed as p24 antigen levels at escalating concentrations2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.
AID264212Inhibition of CCR3 expressed in CHO cells at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID246777Effective concentration to inhibit the replication of HIV-1 R5 strain2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
New approaches toward anti-HIV chemotherapy.
AID264216Protein binding in human plasma2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID264210Inhibition of CCR1 expressed in CHO cells at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID264206Inhibition of [125I]RANTES binding to human CCR5 expressed in CHO cells2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID264209Ability to block RANTES-induced calcium mobilization in HeLa cells expressing CCR5 receptor2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID1256142Selectivity ratio of ED50 for antinociceptive activity in i.c.v dosed ICR-CD1 mouse to ED50 for i.t dosed ICR-CD1 mouse2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).
AID1256135Antagonist activity at CCR5 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of CCl5-induced calcium release at 1 uM by FLIPR assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).
AID237847Oral bioavailability in monkeys2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
New approaches toward anti-HIV chemotherapy.
AID264214Inhibition of CCR7 expressed in CHO cells at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID1256148Antinociceptive activity in LPS-induced ICR-CD1 mouse thermal hyperalgesia model assessed as withdrawal latency for radiant heat at 1000 pmol i.c.v by tail flick assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).
AID246130Effective concentration to inhibit the replication of HIV-1 R5 strain2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
New approaches toward anti-HIV chemotherapy.
AID279329Ratio of IC50 for HIV1 KK infected PBMC to IC50 for compound treated HIV1 KK infected PBMC after 67 passages2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.
AID264211Inhibition of CCR2 isoform B expressed in CHO cells at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1346815Human CCR5 (Chemokine receptors)2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.33 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]